Name | Number of supported studies | Average coverage | |
---|---|---|---|
hepatocyte | 6 studies | 80% ± 17% | |
endothelial cell of sinusoid | 3 studies | 32% ± 15% | |
hepatic stellate cell | 3 studies | 56% ± 26% | |
astrocyte | 3 studies | 21% ± 7% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
liver | 4 studies | 61% ± 14% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
liver | 100% | 117768.33 | 226 / 226 | 99% | 819.02 | 403 / 406 |
pancreas | 100% | 15858.73 | 328 / 328 | 55% | 13.02 | 98 / 178 |
prostate | 64% | 228.53 | 157 / 245 | 38% | 2.67 | 193 / 502 |
uterus | 85% | 38.16 | 145 / 170 | 11% | 0.70 | 52 / 459 |
brain | 80% | 44.57 | 2120 / 2642 | 14% | 0.36 | 101 / 705 |
lung | 64% | 72.48 | 369 / 578 | 30% | 19.83 | 352 / 1155 |
stomach | 62% | 21.42 | 223 / 359 | 11% | 1.95 | 31 / 286 |
adrenal gland | 56% | 17.91 | 145 / 258 | 3% | 0.09 | 7 / 230 |
ovary | 54% | 15.76 | 98 / 180 | 1% | 0.01 | 3 / 430 |
thymus | 51% | 19.53 | 333 / 653 | 1% | 0.01 | 4 / 605 |
breast | 37% | 24.43 | 172 / 459 | 7% | 2.22 | 75 / 1118 |
intestine | 34% | 11.02 | 333 / 966 | 10% | 5.44 | 51 / 527 |
kidney | 39% | 13.35 | 35 / 89 | 3% | 0.54 | 25 / 901 |
spleen | 40% | 248.50 | 96 / 241 | 0% | 0 | 0 / 0 |
esophagus | 30% | 11.39 | 440 / 1445 | 8% | 2.40 | 14 / 183 |
peripheral blood | 32% | 86.28 | 299 / 929 | 0% | 0 | 0 / 0 |
bladder | 24% | 5.76 | 5 / 21 | 7% | 2.65 | 37 / 504 |
blood vessel | 26% | 8.71 | 348 / 1335 | 0% | 0 | 0 / 0 |
adipose | 23% | 31.13 | 279 / 1204 | 0% | 0 | 0 / 0 |
skin | 14% | 6.32 | 259 / 1809 | 4% | 0.22 | 21 / 472 |
heart | 18% | 7.07 | 158 / 861 | 0% | 0 | 0 / 0 |
muscle | 12% | 3.05 | 97 / 803 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 2% | 0.05 | 1 / 45 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0002250 | Biological process | adaptive immune response |
GO_0070527 | Biological process | platelet aggregation |
GO_0050868 | Biological process | negative regulation of T cell activation |
GO_0050776 | Biological process | regulation of immune response |
GO_0072574 | Biological process | hepatocyte proliferation |
GO_0007160 | Biological process | cell-matrix adhesion |
GO_0005577 | Cellular component | fibrinogen complex |
GO_0005615 | Cellular component | extracellular space |
GO_0005576 | Cellular component | extracellular region |
GO_0062023 | Cellular component | collagen-containing extracellular matrix |
GO_0005102 | Molecular function | signaling receptor binding |
GO_0005515 | Molecular function | protein binding |
Gene name | FGL1 |
Protein name | Fibrinogen-like protein 1 (HP-041) (Hepassocin) (HPS) (Hepatocyte-derived fibrinogen-related protein 1) (HFREP-1) (Liver fibrinogen-related protein 1) (LFIRE-1) |
Synonyms | HFREP1 |
Description | FUNCTION: Immune suppressive molecule that inhibits antigen-specific T-cell activation by acting as a major ligand of LAG3 . Responsible for LAG3 T-cell inhibitory function . Binds LAG3 independently from MHC class II (MHC-II) . Secreted by, and promotes growth of, hepatocytes . . |
Accessions | ENST00000381841.4 Q08830 ENST00000381840.5 ENST00000522444.5 ENST00000518650.5 ENST00000427924.5 ENST00000398056.6 ENST00000398054.5 |